Solve Therapeutics Raises $120M to Advance Next-Generation ADCs for Solid Tumors

Solve Therapeutics has raised $120 million in an oversubscribed funding round led by Yosemite, with participation from investors such as Merck & Co., Abingworth, Ally Bridge Group, B Capital, and others. This brings Solve's total capital raised to $321 million since its inception315.

The new capital will accelerate the development of Solve’s clinical-stage antibody-drug conjugates (ADCs), targeting solid tumor malignancies using its proprietary CloakLink™ linker technology345.

Solve’s leading ADC candidates, SLV-154 and SLV-324, are both currently in Phase 1 clinical trials for various solid tumors; the funding will support the completion of Phase 1b studies and expand operational capabilities314.

CloakLink™ linker technology is designed to improve ADC pharmacokinetics and stability, decrease hydrophobicity, and allow for higher drug loading while maintaining reduced toxicity and improved therapeutic index345.

SLV-154 is being tested against multiple tumors, including head and neck, non-small cell lung, small cell lung, and bladder cancers, while the specific tumor targets for SLV-324 have not yet been disclosed1.

Solve Therapeutics was founded by oncology veterans behind previous biotechs acquired by major pharma companies (VelosBio by Merck, Acerta Pharma by AstraZeneca), and integrates novel linker engineering with diagnostics for precision oncology31.

The company reports that clinical trial enrollment is proceeding ahead of schedule and that it plans to share more data as it emerges, with investor interest seen as a strong validation of its platform and strategy13.

Sources:

1. https://www.biopharmadive.com/news/solve-therapeutics-adc-biotech-startup-financing/805450/

3. https://www.businesswire.com/news/home/20251117481427/en/Solve-Therapeutics-Raises-$120-Million-to-Develop-Best-in-Class-ADCs-for-Solid-Tumors

4. https://pulse2.com/solve-therapeutics-120-million-to-advance-next-generation-adc-pipeline-for-solid-tumors/

5. https://trial.medpath.com/news/fa2f5fd317d3c4b9/solve-therapeutics-secures-120-million-to-advance-next-generation-adc-platform-for-solid-tumors